PSIVIDA CORPORATION | 2,843 Euro | +0,222 +8,47 % | |
| WKN: A0Q4DQ ISIN: US74440J1016 Ticker-Symbol: PV3A | Frankfurt | 18.06.13 | 09:30 Uhr |
Branche NanotechnologieAktienmarkt Sonstige |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 17.06. | pSivida stock rises after being named as a takeover target | 35 | bizjournals | |
| 17.06. | pSivida Corporation And Trius Therapeutics: Takeover Targets In 2013 | 24 | Seeking Alpha | |
| 17.06. | PSIVIDA CORP.: UK's NICE issues draft guidance recommending Iluvien for DME | 13 | ASX | |
| 14.06. | pSivida (PSDV) ILUVIEN Receives Recommendation from NICE as Pseudophakic Treatment | 13 | StreetInsider.com | |
| 14.06. | pSivida Corp. Announces UK's NICE Says Yes to ILUVIEN in Some Patients with Diabetic Macular Edema in New Draft Guidance | 20 | Business Wire | |
| pSivida Corp. (NASDAQ:PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's... Mehr lesen zu: pSivida Corp. Announces UK's NICE Says Yes to ILUVIEN in Some Patients with Diabetic Macular Edema in New Draft Guidance | ||||
| 05.06. | What Iluvien May Mean To Alimera And PSivida | 47 | Seeking Alpha | |
| 05.06. | pSivida Drug Technology And Pipeline Make It One Of The Most Undervalued Biotechs For 2013 | 26 | Seeking Alpha | |
| 04.06. | PSIVIDA CORP.: Appendix 3B | 17 | ASX | |
| 30.05. | PSIVIDA CORP.: New tech evaluation agreement with global pharma | 26 | ASX | |
| 29.05. | pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company | 27 | Benzinga.com | |
| 29.05. | pSivida (PSDV) Enters Funded Tech Evaluation Agreement | 10 | StreetInsider.com | |
| 20.05. | PSivida Corporation And GTx: 2 Of The Most Undervalued Biotechs For 2013 | 78 | Seeking Alpha | |
| 15.05. | PSIVIDA CORP.: Form 10-Q | 19 | ASX | |
| 14.05. | pSivida Corp's CEO Discusses Q3 2013 Results - Earnings Call Transcript | 26 | Seeking Alpha | |
| 14.05. | PSIVIDA CORP.: pSivida Corp. third quarter fiscal year 2013 results | 21 | ASX | |
| 13.05. | pSivida Corp. - 8-K, Current Report | 13 | SEC Filings | |
| 08.05. | pSivida Iluvien available in Germany | 23 | Pharma Bus Review | |
| 08.05. | pSivida Corporation achieves commercial launch of eye disease treatment in Germany | 16 | Proactive Investors | |
| 08.05. | PSIVIDA CORP.: pSivida's Iluvien launches in Germany- first patient treated | 7 | ASX | |
| 07.05. | pSivida Announces Commercial Launch of ILUVIEN in Germany with First Patient Treated | 1 | Benzinga.com | |
Seite: 1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| DIVERSA | 0,006 | 0 % | DIVERSA LIMITED: Change of Director's Interest Notice |
| ALTAIR NANOTECHNOLOGIES | 1,701 | -0,18 % | ALTAIR NANOTECHNOLOGIES INC - 8-K, Current Report |
| HEADWATERS | 7,68 | +1,27 % | Headwaters is Among the Companies in the Construction Materials Industry With the Lowest Sales per Share |
| NANOPHASE TECHNOLOGIES | 0,203 | +0,50 % | Lowest Sales per Share in the Specialty Chemicals Industry Detected in Shares of Nanophase Technologies |
| ACACIA RESEARCH | 18,156 | -0,60 % | Acacia Subsidiary Obtains US and Canadian Patents Relating to Energy Efficiency |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von